Meta‐analysis of the effects of sodium glucose cotransporter 2 inhibitors in non‐alcoholic fatty liver disease patients with type 2 diabetes. This evidence concerns the gene SLC5A2 and metabolic dysfunction-associated steatotic liver disease.